246 related articles for article (PubMed ID: 36963632)
21. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
22. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
23. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.
Home PD; Mehta R; Hafidh KAS; Gurova OY; Alvarez A; Serafini P; Pourrahmat MM
Diabetes Obes Metab; 2021 Dec; 23(12):2660-2669. PubMed ID: 34402153
[TBL] [Abstract][Full Text] [Related]
25. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
[TBL] [Abstract][Full Text] [Related]
26. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
Giorgino F; Caruso I; Napoli R
Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
[TBL] [Abstract][Full Text] [Related]
27. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
Perreault L; Rodbard H; Valentine V; Johnson E
Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
[TBL] [Abstract][Full Text] [Related]
28. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Ferrannini E; Niemoeller E; Dex T; Servera S; Mari A
Diabetes Obes Metab; 2022 Jun; 24(6):1159-1165. PubMed ID: 35257461
[TBL] [Abstract][Full Text] [Related]
29. Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.
Kawaguchi Y; Hajika Y; Rinka M; Masumoto K; Sawa J; Hamazaki K; Kumeda Y
J Diabetes Investig; 2024 May; 15(5):598-607. PubMed ID: 38258482
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
[TBL] [Abstract][Full Text] [Related]
31. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
Lingvay I; Handelsman Y; Linjawi S; Vilsbøll T; Halladin N; Ranc K; Liebl A
Endocr Pract; 2019 Feb; 25(2):144-155. PubMed ID: 30383495
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
[TBL] [Abstract][Full Text] [Related]
33. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
Inoue M; Lorenz M; Muto H; Wesch R; Hashimoto Y
Diabetes Obes Metab; 2019 Aug; 21(8):2001-2005. PubMed ID: 31050109
[TBL] [Abstract][Full Text] [Related]
34. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
Mehta R; Billings LK; Liebl A; Vilsbøll T
Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
[TBL] [Abstract][Full Text] [Related]
36. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
[TBL] [Abstract][Full Text] [Related]
37. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
[No Abstract] [Full Text] [Related]
38. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
[TBL] [Abstract][Full Text] [Related]
39. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
[TBL] [Abstract][Full Text] [Related]
40. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
Davidson JA; Desouza C; Fonseca V; Frias JP; Van Gaal L; Giorgino F; Chao J; Dex TA; Roberts M; Saremi A; Leiter LA
Diabet Med; 2020 Feb; 37(2):256-266. PubMed ID: 31365765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
